Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.

If you own Nektar Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at [e-mail], or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005688/en/

The Nektar Therapeutics Stock at the time of publication of the news with a raise of +4,21 % to 2,72EUR on Nasdaq stock exchange (01. Februar 2023, 02:00 Uhr).